Immuno-Oncology Essentials for Oncology Nurses Part 1: Principles & Clinical Advances of I-O Question Title * 1. How knowledgeable are you on the ways in which immuno-oncology agents exert their actions to fight cancer? Not at all knowledgeable Somewhat knowledgeable Moderately knowledgeable Very knowledgeable Extremely knowledgeable OK Question Title * 2. Which of the following statements is correct? Innate immunity is antigen-specific Cell-mediated immunity is mediated by antibodies The immune system can recognize and eliminate cancer cells via adaptive immune mechanisms Immune checkpoint inhibitors bind to activating receptors on T cells allowing them to proliferate and kill cancer cells None of the above OK Question Title * 3. If our immune system is able to detect and destroy abnormal tumour cells, how do these cells develop into cancer? There may be too many tumour cells for the immune response to handle alone, ultimately leading to cancer progression Some tumour cells have acquired the ability to evade detection by expressing proteins to suppress the immune response Some tumour cells do not express antigens in order to be recognized by the immune system All of the above OK Question Title * 4. Which known molecules contribute to T-cell inhibition? CD28 CTLA-4 PD-1 CD28 and CTLA4 CD28 and PD-1 CTLA-4 and PD-1 CD28, CTLA4, and PD-1 OK Question Title * 5. How many immune checkpoint inhibitors are currently approved (as of July 2017) by Health Canada to treat cancer? None (still in development or under review) One Two Three More than three I’m not sure OK Question Title * 6. Select a way in which I-O agents differ from standard chemotherapy? The advantage of I-O agents is that they do not harm healthy cells There may be an appearance of tumour growth or new lesions after I-O treatment Tumours shrink quicker with I-O treatment than with standard therapies I-O treatments only work as long as the drug is in the system All of the above OK DONE